Experimental pleural empyema model in rabbits: Why, how and what are the next steps
Abstract
Bacgraund/Aim. The use of new therapeutic methods to prevent development of fibrothorax as the final complication of the human pleural infections requires research with experimental animals. The aim of this study was to standardize the procedures for the establishment of our own experimental model of empyema in rabbits, since it should be able to offer similar conditions found in human pleural infections. Methods. This experiment included 15 chinchilla rabbits, weighing from 2.3 to 2.8 kg. There were 12 rabbits in the experimental group, while 3 rabbits formed the control group. On the first day, we administered 0.4–0.5 mL of turpentine in the right pleural space of the rabbits from the experimental group in order to provoke sterile exudative pleurisy. After 24 h we injected 1 mL of Staphylococcus aureus and 1 mL of Escherichia coli bacteria in the same concentration of 4.5 ´ 108 bacteria/mL. Thoracocentesis for the pleural fluid analysis was performed 24, 48, 72, and 96 h after bacteria instillation. In these pleural samples we estimated the number of leucocytes and the values of lactate dehydrogenase (LDH), glucose and pH in pleural fluid, as well as the presence of bacteria. We did not protect the animals with antibiotics, and on the day 7 of the experiment they were sacrificed with the lethal dose of barbiturate (iv). The lung from the empyemic side of all experimental animals and the lung of one control animal were histopathologically examined. Results. A total of 4 animals had a small amount of clear pleural fluids or there was no fluid obtained with thoracocentesis 24 and 48 h after the bacteria instillation. In the remaining 8 rabbits 24 h after bacteria administration the mean values (± SD) of the parameters monitored were as follows: Le 34.75 ± 6.13 ´ 109/L, LDH 17,000 ± 4,69 U/L, glucose 1.23 ± 0.45 mmol/L, and pH 6.975 ± 0.15. The obtained values met the criteria for the evaluation of effusion as pleural empyema or complex and complicated pleural effusion (LDH > 1000 U/L, glucose < 2.31 mmol/L and pH < 7.20). Bacterial cultures were positive in 5 out of 8 first pleural samples and in only 2 samples after 48 h of bacteria administration. There was a positive correlation between the number of leukocytes and the LDH value (r = 0.071, p < 0.001), and a negative correlation between the number of leukocytes and the glucose level (r = 0.864, p < 0.001), and the leukocytes number and pH of the pleural fluid (r = 0.894, p < 0.001). The mean glucose value increased after 48 h (3.23 ± 0.44 mmol/L), and the pH value rose after 72 h (7.22 ± 0.03) which was beyond the empyema level. Conclusion. The creation of the experimental empyema model is a very delicate work with uncertain success. Its value and importance are crucial for pleural pathology research. With the intention to obtain a more empyemic pleural reaction we created a model with two different human pathogen bacteria. We generated the satisfactory results, but not as good as those contained in some of the reference literature data.
References
Roberts JR. Minimally invasive surgery in the treatment of em-pyema: intraoperative decision making. Ann Thorac Surg 2003; 76(1): 225−30.
Mandal AK, Thadepalli H. Mandal Aloke K, Chettipally U. Out-came of Primary Empyema Thoracis: Therapeutic and Micro-biologic Aspects. Ann Thorac Surg 1998; 66(5): 1782−6.
Sasse S, Nguyen T, Teixeira LR, Light R. The utility of daily the-rapeutic thoracentesis for the treatment of early empyema. Chest 1999; 116(6): 1703−8.
Novakov IP, Peshev ZV, Popova TA, Tuleva SD. Experimental Pleural Empyema in Rabbits-Cellular and Biochemical Changes. Trakia J Sci 2005; 3(1): 26.
Lemense GP, Strange C, Sahn SA. Empyema thoracis. Therapeu-tic management and outcome. Chest 1995; 107(6): 1532−7.
Light RW. Parapneumonic Effusions and Empyema. Am Thorac Soc 2006; 3(1): 75−80.
Cohen M, Sahn SA. Resolution of pleural effusions. Chest 2001; 119(5): 1547−62.
Mackenzie JW. Video-Assisted Thoracoscopy: Treatment for Empyema and Hemothorax. Chest 1996; 109(1): 2−3.
Liapakis IE, Light RW, Pitiakoudis MS, Karayiannakis AJ, Giama-rellos-Bourboulis EJ, Ismailos G, et al. Penetration of clarithromycin in experimental pleural empyema model fluid. Respiration 2005; 72(3): 296−300.
Molnar TF. Current surgical treatment of thoracic empyema in adults. Eur J Cardiothorac Surg 2007; 32(3): 422−30.
Luh S, Chou M, Wang L, Chen J, Tsai T. Video-assisted thora-coscopic surgery in the treatment of complicated parapneu-monic effusions or empyemas: outcome of 234 patients. Chest 2005; 127(4): 1427−32.
Wait MA, Sharma S, Hohn J, Dal NA. A randomized trial of empyema therapy. Chest 1997; 111(6): 1548−51.
Graham EA, Bell RD. Open pneumothorax: its relations to the treatment of empyema. Am J Med Sci 1918; 156(6): 839−71.
Sasse S, Nguyen TK, Mulligan M, Wang NS, Mahutte CK, Light RW. The effects of early chest tube placement on empyema resolution. Chest 1997; 111(6): 1679−83.
Shohet I, Yellin A, Meyerovitch J, Rubinstein E. Pharmacokinetics and Therapeutic Efficacy of Gentamicin in an Experimental Pleural Empyema Rabbit Model. Antimicrob Agents Che-mother 1987; 31(7): 982−5.
Na MJ, Dikensoy O, Light RW. New trends in the diagnosis and treatment in parapneumonic effusion and empyema. Tuberk Toraks 2008; 56(1): 113−20.
Kunz CR, Jadus MR, Kukes GD, Kramer F, Nguyen VN, Sasse SA. Intrapleural injection of transforming growth factor-beta antibody inhibits pleural fibrosis in empyema. Chest 2004; 126(5): 1636−44.
Cheng G, Vintch JRE. A Retrospectiv Analysis of the Managa-ment of Parapneumonic Empyemas in County Teaching Facil-ity From 1992 to 2004. Chest 2005; 128(5): 3284−90.
Zhu Z, Hawthorne ML, Guo Y, Drake W, Bilaceroglu S, Misra HL, et al. Tissue plasminogen activator combined with human re-combinant deoxyribonuclease is effective therapy for empye-ma in a rabbit model. Chest 2006; 129(6): 1577−83.
Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000; 118(4): 1158−71.
Berger HA, Morganroth ML. Immediate drainage is not required for all patients with complicated parapneumonic effusions. Chest 1990; 97(3): 731−5.
Storm HK, Krasnik M, Bang K, Frimodt-Møller N. Treatment of pleural empyema secondary to pneumonia: thoracocentesis re-gimen versus tube drainage. Thorax 1992; 47(10): 821−4.
Heffner JE. Multicenter Trials of Treatment for Empyema - Af-ter All These Years. N Engl J Med 2005; 352(9): 926−8.
Sasse SA, Causing LA, Mulligan ME, Light RW. Serial pleural fluid analysis in a new experimental model of empyema. Chest 1996; 109(4): 1043−8.
Sahn SA, Potts DE. Turpentine pleurisy in rabbits: a model of pleural fluid acidosis and low pleural fluid glucose. Am Rev Respir Dis 1978; 118(5): 893−901.
Liapakis IE, Kottakis I, Tzatzarakis MN, Tsatsakis AM, Pitiakou-dis MS, Ypsilantis P, et al. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004; 24(3): 466−70.
Saroglou M, Ismailos G, Tryfon S, Liapakis I, Papalois A, Bouros D. Penetration of azithromycin in experimental pleural empyema fluid. Eur J Pharmacol 2010; 626(2−3): 271−5.
Saroglou M, Tryfon S, Ismailos G, Liapakis I, Tzatzarakis M, Tsat-sakis A, et al. Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion. J Inflamm (Lond) 2010; 7(1): 22.
Mavroudis C, Ganzel BL, Katzmark S, Polk HC. Effect of hemo-thorax on experimental empyema thoracis in the guinea pig. J Thorac Cardiovasc Surg 1985; 89(1): 42−9.
Bhattacharyya N, Umland ET, Kosloske AM. A bacteriologic basis for the evolution and severity of empyema. J Ped Surg 1994; 29(5): 667−70.
Strahilevitz J, Lev A, Levi I, Fridman E, Rubinstein E. Experimen-tal pneumococcal pleural empyema model: the effect of moxif-loxacin. J Antimicrob Chemother 2003; 51(3): 665−9.
